Professor Jonathan N Weber

Publications


Journals

  • White P; Fox J; MacDonald N; Weber J; McClure M; Fidler S; Ward H. (1 Jul 2011). HOW MANY INFECTIONS ARE AVERTED BY BEHAVIOUR CHANGE AFTER EARLY HIV DIAGNOSIS & COUNSELLING OF MSM? ESTIMATES FROM A STOCHASTIC INDIVIDUAL-BASED MODEL. SEXUALLY TRANSMITTED INFECTIONS. 87:A51-A52. Author weblink DOI.
  • English S; Katzourakis A; Bonsall D; Flanagan P; Duda A; Fidler S; Weber J; McClure M; et alPhillips R; Frater J. (7 Jul 2011). Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants. RETROVIROLOGY. 8. Author weblink DOI.
  • Fox J; White PJ; Weber J; Garnett GP; Ward H; Fidler S. (10 Sep 2011). Could we, should we? Yes. AIDS. 25:1801. DOI.
  • Erlwein O; Robinson MJ; Dustan S; Weber J; Kaye S; McClure MO. (2011). DNA extraction columns contaminated with murine sequences. PLoS One. 6:e23484. DOI.
  • English S; Katzourakis A; Bonsall D; Flanagan P; Duda A; Fidler S; Weber J; McClure M; et alSPARTAC Trial Investigators; Phillips R; Frater J. (2011). Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants. Retrovirology. 8:54. DOI.
  • Guimaraes-Walker A; Mackie N; McCormack S; Hanke T; Schmidt C; Gilmour J; Barin B; McMichael A; et alWeber J; Legg K; Babiker A; Hayes P; Gotch F; Smith C; Dally L; Dorrell L; Cebere I; Kay R; Winstone N; Moore S; Goonetilleke N; Fast P. (18 Apr 2011). Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers (vol 26, pg 6671, 2008). VACCINE. 29:3511-3511. DOI.
  • Fox J; White PJ; Weber J; Garnett GP; Ward H; Fidler S. (15 May 2011). Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS. 25:1065-1082. DOI.
  • Erlwein O; Robinson MJ; Kaye S; Wills G; Izui S; Wessely S; Weber J; Cleare A; et alCollier D; McClure MO. Investigation into the Presence of and Serological Response to XMRV in CFS patients. DOI.
  • Robinson M; Erlwien O; Kaye S; Weber J; Cingoz O; Patel A; Walker M; Kim W; et alUiprasertkul M; Coffin J; McClure M. Mouse DNA contamination in human tissue tested for XMRV. Retrovirology. Author weblink DOI.
  • Robinson MJ; Erlwein OW; Kaye S; Weber J; Cingoz O; Patel A; Walker MM; Kim WJ; et alUiprasertkul M; Coffin JM; McClure MO. (2010). Mouse DNA contamination in human tissue tested for XMRV. Retrovirology. 7:108. DOI.
  • Thomson EC; Fleming VM; Main J; Klenerman P; Weber J; Eliahoo J; Smith J; McClure MO; et alKarayiannis P. (Jun 2011). Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 60:837-845. DOI.
  • Weber J; Tatoud R; Fidler S. (Oct 2010). Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS. 24 Suppl 4:S27-S39. DOI.
  • Huang KH; Bonsall D; Katzourakis A; Thomson EC; Fidler SJ; Main J; Muir D; Weber JN; et alFrater AJ; Phillips RE; Pybus OG; Goulder PJ; McClure MO; Cooke GS; Klenerman P. (2010). B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun. 1:102. DOI.
  • Barnes E; Flanagan P; Brown A; Robinson N; Brown H; McClure M; Oxenius A; Collier J; et alWeber J; Günthard HF; Hirschel B; Fidler S; Phillips R; Frater J. (15 Nov 2010). Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. J Infect Dis. 202:1482-1485. DOI.
  • McCormack S; Ramjee G; Kamali A; Rees H; Crook AM; Gafos M; Jentsch U; Pool R; et alChisembele M; Kapiga S; Mutemwa R; Vallely A; Palanee T; Sookrajh Y; Lacey CJ; Darbyshire J; Grosskurth H; Profy A; Nunn A; Hayes R; Weber J. (16 Oct 2010). PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 376:1329-1337. DOI.
  • Fox J; Castro H; Kaye S; McClure M; Weber JN; Fidler S; UK Collaborative Group on HIV Drug Resistance. (24 Sep 2010). Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-2401. DOI.
  • Erlwein O; Kaye S; McClure MO; Weber J; Wills G; Collier D; Wessely S; Cleare A. (2010). Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One. 5:e8519. DOI.
  • Fox J; White PJ; Macdonald N; Weber J; McClure M; Fidler S; Ward H. (Aug 2009). Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med. 10:432-438. DOI.
  • Wilson SL; Scullard G; Fidler SJ; Weber JN; Poulter NR. (Jul 2009). Effects of HIV status and antiretroviral therapy on blood pressure. HIV Med. 10:388-394. DOI.
  • Kawashima Y; Pfafferott K; Frater J; Matthews P; Payne R; Addo M; Gatanaga H; Fujiwara M; et alHachiya A; Koizumi H; Kuse N; Oka S; Duda A; Prendergast A; Crawford H; Leslie A; Brumme Z; Brumme C; Allen T; Brander C; Kaslow R; Tang J; Hunter E; Allen S; Mulenga J; Branch S; Roach T; John M; Mallal S; Ogwu A; Shapiro R; Prado JG; Fidler S; Weber J; Pybus OG; Klenerman P; Ndung'u T; Phillips R; Heckerman D; Harrigan PR; Walker BD; Takiguchi M; Goulder P. (2 Apr 2009). Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 458:641-645. DOI.
  • Fox J; Alsop A; Elam G; Green J; Weber J; Ward H; McClure M; Fidler S. (1 Apr 2009). Understanding HIV-risk behaviour in HIV-serodiscordant couples - a novel approach. HIV MEDICINE. 10:54-54. Author weblink.
  • Fox J; Willberg C; Ziprin P; Goldin R; Weber J; McClure M; Klenerman P; Fidler S. (1 Apr 2009). The role of the gut mucosa in protection from HIV-1 in highly exposed persistently seronegative individuals (HEPS). HIV MEDICINE. 10:5-5. Author weblink.
  • McCormack S; Taylor D; Richardson B; Darbyshire J; Sattentau Q; Karim QA; Karim SS; Kharsany A; et alLacey C; Nunn A; Weber J. (Mar 2009). Re: "Enhancement of HIV infection by cellulose sulfate," by Tao et al. AIDS Res Hum Retroviruses. 25:373. DOI.
  • English S; Katzourakis A; Flanagan P; Duda A; Francis J; Matthews P; Prendergast A; Goulder P; et alFidler S; Weber J; McClure M; Phillips R; Frater J. (1 Jan 2009). Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients. RETROVIROLOGY. 6. Author weblink.
  • Duda A; Lee-Turner L; Fox J; Robinson N; Dustan S; Kaye S; Fryer H; Carrington M; et alMcClure M; McLean AR; Fidler S; Weber J; Phillips RE; Frater AJ; SPARTAC Trial Investigators. (Feb 2009). HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol. 83:1228-1239. DOI.
  • Guimarães-Walker A; Mackie N; McCormack S; Hanke T; Schmidt C; Gilmour J; Barin B; McMichael A; et alWeber J; Legg K; Babiker A; Hayes P; Gotch F; Smith C; Dally L; Dorrell L; Cebere I; Kay R; Winstone N; Moore S; Goonetilleke N; Fast P; IAVI-006 Study Group. (2 Dec 2008). Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine. 26:6671-6677. DOI.
  • Midgley CM; Putz MM; Weber JN; Smith GL. (Dec 2008). Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol. 89:2992-2997. DOI.
  • McCormack S; Stöhr W; Barber T; Bart PA; Harari A; Moog C; Ciuffreda D; Cellerai C; et alCowen M; Gamboni R; Burnet S; Legg K; Brodnicki E; Wolf H; Wagner R; Heeney J; Frachette MJ; Tartaglia J; Babiker A; Pantaleo G; Weber J. (13 Jun 2008). EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 26:3162-3174. DOI.
  • Bart PA; Goodall R; Barber T; Harari A; Guimaraes-Walker A; Khonkarly M; Sheppard NC; Bangala Y; et alFrachette MJ; Wagner R; Liljeström P; Kraehenbuhl JP; Girard M; Goudsmit J; Esteban M; Heeney J; Sattentau Q; McCormack S; Babiker A; Pantaleo G; Weber J; EuroVacc Consortium. (13 Jun 2008). EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine. 26:3153-3161. DOI.
  • Gray K; Legg K; Sharp A; Mackie N; Olarinde F; De Souza C; Weber J; Peters B. (2 Jun 2008). Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine. 26:2919-2924. DOI.
  • Fox J; Scriba TJ; Robinson N; Weber JN; Phillips RE; Fidler S. (Jun 2008). Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clin Exp Immunol. 152:532-537. DOI.
  • Fox J; Nastouli E; Thomson E; Muir D; McClure M; Weber J; Fidler S. (12 Mar 2008). Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS. 22:666-668. DOI.
  • Fidler S; Fox J; Porter K; Weber J. (Feb 2008). Primary HIV infection: to treat or not to treat?. Curr Opin Infect Dis. 21:4-10. DOI.
  • Harari A; Bart PA; Stöhr W; Tapia G; Garcia M; Medjitna-Rais E; Burnet S; Cellerai C; et alErlwein O; Barber T; Moog C; Liljestrom P; Wagner R; Wolf H; Kraehenbuhl JP; Esteban M; Heeney J; Frachette MJ; Tartaglia J; McCormack S; Babiker A; Weber J; Pantaleo G. (21 Jan 2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 205:63-77. DOI.
  • Gantlett KE; Weber JN; Sattentau QJ. (Sep 2007). Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res. 75:188-197. DOI.
  • Fidler S; Fox J; Touloumi G; Pantazis N; Porter K; Babiker A; Weber J. (19 Jun 2007). Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS. 21:1283-1291. DOI.
  • Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Moreau Y; Shafer RW; Van Laethem K; et alCarvalho AP; Wynhoven B; Cane P; Snoeck J; Clarke J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Shapiro JM; Katzenstein DA; Kantor R; Vandamme AM. (Jun 2007). Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect Genet Evol. 7:382-390. DOI.
  • Kaleebu P; Nankya IL; Yirrell DL; Shafer LA; Kyosiimire-Lugemwa J; Lule DB; Morgan D; Beddows S; et alWeber J; Whitworth JA. (1 May 2007). Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr. 45:28-33. DOI.
  • Fox Z; Antunes F; Davey R; Gazzard B; Klimas N; Labriola A; Losso M; Neaton JD; et alPhillips AN; Ruxrungtham K; Staszewski S; Weiss L; Lundgren JD; Abrams DI; Cooper DA; Abrams DI; Cooper DA; Darbyshire JH; Duncan WR; Emery S; Lane HC; Lehrman S; Lundgren JD; Neaton JD; Aguilar L; Betina Angel E; Aquilia S; Belloso W; Benetucci J; Bittar V; Cahn P; Casiro A; Contarelli J; Corral J; Daciuk L; David D; Ferrari I; Fridman D; Galache V; Guaragna G; Ivalo S; Laplume H; Lanusse I; Lasala MB; Lattes R; Lasovsky J; Lopardo G; Losso M; Lourtau L; Lupo S; Maranzana A; Marson C; Massera L; del Lujan Sanchez M; Somenzini C; Tocci M; Algar S; Anderson J; Baker D; Blavius K; Bloch M; Boyle M; Bradford D; Britton P; Carrall L; Carr A; Chuah J; Curry M; D'Arcy-Evans C; Dobson P; Doong N; Egan C; Ferguson W; Finlayson R; French M; Frater A; Gold J; Habel P; Haig K; Holland R; Hyland N; Hoy J; Hudson J; James R; Leung J; Lowe K; MacRae K; McMurchie M; Medland N; Miller S; Murray J; Newman R; Orth D; Patching J; Primrose R; Ree H; Richardson R; Rogers G; Roney J; Roth N; Sarangapany J; Shaw D; Silberberg C; Skett J; Williams L; Soo TM; Sowden D; Street A; Vale R; Villella C; Walker A; Watson A; Wendt N; Wood H; Youds D; Aichelburg A; Rieger A; Vetter N; Clumeck N; De Wit S; Kabeya K; O'Doherty E; Amorim CDS; Basso CR; Lewi DS; Pereira LC; da Silva M; Lobato Souza TN; Angel J; Bouchard P-R; Clark F; Cohen J; Dambreville M; Ellis M; Fiset S; Foster A; Fraser C; Gagnon S; Gilmour J; Guenette R; Haldane H; Hawley-Foss N; Hyndman S; Johnston L; Jubinville N; Juneau F; Kelleher L; LaPointe L; Latendre-Paquette J; Lindemulder A; Mashinter L; Lefebvre E; McFarland N; Morisseau C; O'Neill R; Piche A; Ralph E; Rouleau D; Routy J-P; Sandre R; Schmidt S; Shafran S; Smaill F; Stromberg D; Trepanier J-M; Trottier S; Veal S; Walmsley S; Weiss K; Williams K; Young M; Zaleschuk B; Zarowny D; Baadegaard B; Black F; Boedker K; Gerstoft J; Jensen L; Mathiesen L; Nielsen H; Pedersen C; Petersen D; Aboulker J-P; Baakili A; Bengrait N; Bensalem M; Berthe H; Bloche M; Bazin C; Boue F; Bouvet E; Brancon C; Capitant C; Ceppi C; Cheneau C; Coutellier A; Chennebault JM; Coquet F; De Truchis P; Delavalle A-M; Frixon-Marin V; Gastaut J-A; Delfraissy F; Eliaszeicz M; Gallais H; Gataut J-A; Gilquin J; Gonzalez-Canali G; Gaudebout C; Goujard C; Hoen B; Honore P; Jarousse B; Lang J-M; Lefebvre B; Levy Y; Loison J; Maignan A; Meynard J-L; Michon C; Mole M; Marsal L; Matheron S; Mortier E; Oksenhendler E; Poirier S; Picard-Dahan C; Ravaux I; Raffi F; Raguin G; Reynes J; Rozenbaum W; Salmon D; Simon A; Spiridon G; Viard J-P; Vidal M; Weiss L; Zucman D; Bergmann F; Brockmeyer N; Faetkenheuer G; Fenske S; Gey D; Goebel F-D; Goetsch M; Hartmann M; Klinker H; Kremer G; Mantzsch K; Mauss S; Rockstroh J; Rotty J; Rund E; Schneider K; Schuermann D; Staszweski S; Tilmann K; Vogel M; Bentwich Z; Drora G; Kedem E; Lang R; Levi I; Maayan S; Magen E; Mamorsky M; Pilpul A; Pollack S; Sthoeger Z; Vered H; Yust I; Lyons F; Mulcahy F; Rochford A; Auiti F; Angarano G; Bertelli D; Bini T; Bruno R; Cadeo GP; Carosi G; D'Arminio Monforte A; Del Giacco S; Di Pietro M; Esposito R; Filice G; Gavazzeni G; Guaraldi G; Indiveri F; Lazzarin A; Mazzotta F; Minolli L; Montroni M; Moroni M; Nozza S; Pastor G; Poli G; Raise E; Romagnani S; Rusconi V; Sacchi P; Suter F; Tambussi G; Tirelli U; Fraser H; Iwamoto A; Kikuchi Y; Mori M; Nakamura T; Odawara T; Oka S; Shirasaka T; Takano M; To J; Ueta C; El Filali K; Erradey I; Himmich H; Blok W; Borleffs J; Bravenboer B; Bronveld W; Claessen F; Duurvoort M; Ferwerda J; Frissen P; Hulshoff N; Juttman J; Kauffmann R; Koopmans P; Kroon F; Lowe S; Leemhuis M; Meenhorst P; de Boer LP; Reiss P; Reinders-Folmer S; Richter C; Santegoets R; Schoemaker M; Schrey G; Sprenger H; Ten Veen J; Tessalaar J; van der Ende M; van der Vall H; van Eeden A; van Leeuwen R; Vermeulen J; ten Kate RW; van Boxtel R; van Eden A; van de Ven B; van der Meulen P; ten Napei C; Vriesendrop R; Bruun J; Bakowska E; Beniowski M; Boron-Kaczmarska A; Gasiorowski J; Gxadysz A; Horban A; Knysz B; Mularska E; Pynka M; Szymczak A; Aldir I; Antunes F; Doroana M; Duque L; Mansinho K; Pinto I; Valadas E; Vera J; Foo E; Panchalingham A; Lim PL; Paton N; Peperstraete B; Quek A; Alcazar-Caballero R; Arrizabalaga J; Bouza E; Cepeda C; de Barron X; Cervero Jimenez M; Clotet B; Cortes L; Domingo P; Fernandez P; Fernandez-Cruz E; Fuster M; Gatell J; Gijon P; Gil I; Gonzales-Lahoz J; Gonzalez A; Hernandez M; Iribarren J; Jimenez M; Knobel H; Leon A; Carlos Lopez J; Lozano A; Lopez P; Moreno J; Munoz R; Padilla B; Parras A; Pastor A; Pedreira J; Pristo J; Pena J; Roca V; Rubio R; Sanchez de Rivera J; Sanz J; Tamargo L; Torres R; Pehrson PO; Sandstrom E; Bernasconi E; Gurtner V; Magenta L; Ampunpong U; Bowonwatnuwong C; Chanchai P; Chetchotisakd P; Chuenyam T; Duncombe C; Horsakulthai M; Kantipong P; Liddy J; Phanuphak P; Pongsurachet V; Ruxrungtham K; Seekaew S; Sonjai A; Subsri N; Suwanagool S; Techasathit W; Wankoon J; Adebiyi A; Aldam D; Alexander I; Angus B; Barber T; Bonnington S; Care C; Carroll A; Cornforth D; Donaldson O; Druiff L; Easterbrook P; Edwards B; Ellis C; Erradey I; El Filali K; Fisher M; Fox R; Gazzard B; Harrison A; Herman S; Heald L; Higgs C; Himmich H; Jendrulek I; Johnson M; Judges L; Karim F; Kinghorn G; Laurenti J; Lee C; Leen C; Legg K; Lyons F; Maw R; MacConachie A; McKernan S; McLean L; McMillan A; Mguni S; Morris S; Mulchay F; Mullan D; Mullaney S; Murphy M; Nunn A; Ong E; Owen M; Palfreeman A; Perry N; Peters B; Pozniak A; Rochford A; Ronan A; Skinner C; Stroud C; Takawira M; Tamm N; Thomas R; Yee TT; Vanthuyne A; Wansborough-Jones M; Weber J; White D; Wilkins E; Wiselka M; Williams I; Waugh M; Wotherspoon J; Youle M; Doyle M; Goodwin E; Luskin-Hawk R; Sullivan J; Verheggen R; Abrams D; Baxter J; Besch CL; Child C; Cohn D; Cooper P; El-Sadr W; Farrough M; Fisher E; Fuentes L; Goodwin E; Gordin F; Graeber C; Kelly ME; Kostman J; Labriola A; Lattanzi K; MacArthur R; Makohon L; Markowitz NP; Martinez N; Mastro-Polak D; Mitchell V; Mushatt D; Patterson K; Perez G; Rosmarin C; Rouff JR; Saldanha J; Sampson J; Sawyer R; Standridge B; Sullivan J; Sweeton B; Tedaldi E; Thompson M; Valencia P; Verlinghieri G; Walker J; Watson V; Williams B; Armstrong A; Banks S; Blazes D; Barile A; Coelho L; Dennis M; Flaks H; Gilcrest J; Gittens K; Hopper S; Humphries MJ; Spooner K; Tamminga CL; Vita J; Wegner SA; Wortmann G; Bisby N; Blake W; Brown S; Chilliade P; Cole T; Elliot K; Geisler C; Goetz M; Gomez-Perez E; Gordin F; Helman J; Klimas N; Labriola A; Nahass R; LeFlore D; Marston B; Obregon M; Petrolati J; Pitrak DL; Roland R; Rosa C; Rossman B; Schlueter Wirtz S; Schuck S; Scretchings T; Simon G; Smith M; Standridge B; Summers K; Werhane MJ; Arduino R; Bell B; Breaux K; Cuervo H; Hale C; Lewis S; Mall M; Mora F; Diez MM; Okhuysen P; Rodriguez-Barradas M; Schrader SR; Healy L; Kaszubski C; Kolber M; Tanner T; Armstrong J; Dahlke J; Johnson L; Kaminski P; Rhame F; Shoden C; Temesgen Z; Urbanich M; Valenti S; Zervos M; Davey R; Barrick B; Chaitt D; Hahn B; Lane C; Martell D; McNay L; Metcalf J; Powers A; Tavel JA; Loveless K; Martinez N; Peterson S; Sampson J; Sweek S; Abrams D; Albrecht H; Antoine N; Kelly ME; Pell P; Belloso W; Gatell JM; Hoy J; Lifson A; Pederson C; Rhame F; El-Sadr W; Borup L; Dragsted UB; Greve AF; Jensen K; Lundgren J; Mollerup D; Pearson M; Phillips A; Aboulhab J; Angus B; Babiker A; Cordwell B; Darbyshire J; Hack L; Hooker M; Moraes Y; Newberry D; Nuwagaba-Biribonwoha H; van Hooff F; Denning E; Holland Klemme L; Carey C; Chan F; Cooper D; Courtney-Rodgers D; Drummond F; Emery S; Jacoby S; Law M; Stewart M; Pett S; Alloo Z; Bebchuk J; Bollenbeck P; DuChene AG; Fosdick L; Harrison M; Krum E; Larson G; Lifson A; Meger S; Neaton J; Nelson R; Quan S-FL; Schultz T; Telke S; Thackeray L; Thompson G; Wentworth D; Wyman N; Duncan W; Ferguson E; Fox L; Gettinger N; Herrera J; Lehrman S; Luzar MA; Maeshiro M; Martinez A; Oseekey K; Baigent G; Capra W; Duliege A-M; Fitzgerald L; Kwakkelstein M; Maral J; O'Hara M; Sahner D; Weber C; Adam-Perchec C; Barron N; Bell ML; Dolan S; Eckstrand J; Hicks S; McAuley G; Beck S; Brown S; Rupert A. (1 Mar 2007). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin-2. HIV MEDICINE. 8:112-123. Author weblink.
  • Zimbwa P; Milicic A; Frater J; Scriba TJ; Willis A; Goulder PJ; Pillay T; Gunthard H; et alWeber JN; Zhang HT; Phillips RE. (Feb 2007). Precise identification of a human immunodeficiency virus type 1 antigen processing mutant. J Virol. 81:2031-2038. DOI.
  • Lucas M; Ulsenheimer A; Pfafferot K; Heeg MH; Gaudieri S; Grüner N; Rauch A; Gerlach JT; et alJung MC; Zachoval R; Pape GR; Schraut W; Santantonio T; Nitschko H; Obermeier M; Phillips R; Scriba TJ; Semmo N; Day C; Weber JN; Fidler S; Thimme R; Haberstroh A; Baumert TF; Klenerman P; Diepolder HM. (2007). Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One. 2:e649. DOI.
  • Fox J; Dustan S; McClure M; Weber J; Fidler S. (Oct 2006). Transmitted drug-resistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med. 7:477-483. DOI.
  • Podlekareva D; Mocroft A; Dragsted UB; Ledergerber B; Beniowski M; Lazzarin A; Weber J; Clumeck N; et alVetter N; Phillips A; Lundgren JD; EuroSIDA study group. (1 Sep 2006). Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis. 194:633-641. DOI.
  • Fox J; Weber J; Fidler S. (Aug 2006). Primary HIV. Sex Transm Infect. 82:267-268. DOI.
  • INITIO Trial International Co-ordinating Committee; Yeni P; Cooper DA; Aboulker JP; Babiker AG; Carey D; Darbyshire JH; Floridia M; et alGirard PM; Goodall RL; Hooker MH; Mijch A; Meiffredy V; Salzberger B. (22 Jul 2006). Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 368:287-298. DOI.
  • Frater AJ; Edwards CT; McCarthy N; Fox J; Brown H; Milicic A; Mackie N; Pillay T; et alDrijfhout JW; Dustan S; Clarke JR; Holmes EC; Zhang HT; Pfafferott K; Goulder PJ; McClure MO; Weber J; Phillips RE; Fidler S. (Jul 2006). Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts. J Virol. 80:7226-7234. DOI.
  • Lacey CJ; Wright A; Weber JN; Profy AT. (24 Apr 2006). Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS. 20:1027-1030. DOI.
  • Snoeck J; Kantor R; Shafer RW; Van Laethem K; Deforche K; Carvalho AP; Wynhoven B; Soares MA; et alCane P; Clarke J; Pillay C; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Brun-Vézinet F; Reid C; Cahn P; Brigido LF; Grossman Z; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan RP; Camacho R; Schapiro JM; Katzenstein D; Vandamme AM. (Feb 2006). Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 50:694-701. DOI.
  • Fox JM; Fidler S; Weber J. (21 Jan 2006). Resistance to HIV drugs in UK may be lower in some areas. BMJ. 332:179-180. DOI.
  • Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J. (9 Jan 2006). Comparative potency of three antiretroviral therapy regimes in primary HIV infection. AIDS. 20:247-252. DOI.
  • Taylor GP; Goon P; Furukawa Y; Green H; Barfield A; Mosley A; Nose H; Babiker A; et alRudge P; Usuku K; Osame M; Bangham CR; Weber JN. (2006). Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology. 3:63. DOI.
  • Cane P; Chrystie I; Dunn D; Evans B; Geretti AM; Green H; Phillips A; Pillay D; et alPorter K; Pozniak A; Sabin C; Smit E; Weber J; Zuckerman M; UK Group on Transmitted HIV Drug Resistance. (10 Dec 2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368. DOI.
  • Scriba TJ; Purbhoo M; Day CL; Robinson N; Fidler S; Fox J; Weber JN; Klenerman P; et alSewell AK; Phillips RE. (15 Nov 2005). Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol. 175:6334-6343.
  • Milicic A; Edwards CT; Hué S; Fox J; Brown H; Pillay T; Drijfhout JW; Weber JN; et alHolmes EC; Fidler SJ; Zhang HT; Phillips RE. (Nov 2005). Sexual transmission of single human immunodeficiency virus type 1 virions encoding highly polymorphic multisite cytotoxic T-lymphocyte escape variants. J Virol. 79:13953-13962. DOI.
  • Beddows S; Zheng NN; Herrera C; Michael E; Barnes K; Moore JP; Daniels RS; Weber JN. (20 Jun 2005). Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. Virology. 337:136-148. DOI.
  • Weber J; Desai K; Darbyshire J; Microbicides Development Programme. (May 2005). The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med. 2:e142. DOI.
  • Bobkov AF; Selimova LM; Khanina TA; Zverev SY; Pokrovsky VV; Weber JN; Bobkov EN; Rylkov AV. (Apr 2005). Human immunodeficiency virus type 1 in illicit-drug solutions used intravenously retains infectivity. J Clin Microbiol. 43:1937-1939. DOI.
  • Kantor R; Katzenstein DA; Efron B; Carvalho AP; Wynhoven B; Cane P; Clarke J; Sirivichayakul S; et alSoares MA; Snoeck J; Pillay C; Rudich H; Rodrigues R; Holguin A; Ariyoshi K; Bouzas MB; Cahn P; Sugiura W; Soriano V; Brigido LF; Grossman Z; Morris L; Vandamme AM; Tanuri A; Phanuphak P; Weber JN; Pillay D; Harrigan PR; Camacho R; Schapiro JM; Shafer RW. (Apr 2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112. DOI.
  • Blackham J; Burns S; Cameron S; Cane P; Chrystie I; Churchill D; Clarke J; Easterbrook P; et alZuckerman M; Goldberg D; Gompels M; Hale T; Lazarus L; Leigh-Brown A; Loveday C; Geretti AM; Pillay D; Phillips A; Sabin C; Hill T; Kellam P; Dunn D; Porter K; Green H; Matthias R; Pozniak A; Tilston P; Williams I; Babiker A; Dunn D; Fisher M; Gilson R; Johnson M; Mortimer J; Peters B; Porter K; Scullard G; Gazzard B; Bansi L; Smith C; Waters A; Crates D; Morgan N; Perry N; Pullin A; Harris W; Bulbeck S; Mandalia S; Gilson R; Dodds J; Fudge N; Rider A; Williams I; Sinka K; Evans B; Delpech V; Larbalestier N; Gray K; Johnson M; Youle M; Lampe F; Gumley H; Chaloner C; Puradiredja J; Weber J; Clarke J; Owens C. (25 Mar 2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-494. Author weblink.
  • Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; et alLundgren JD; Phillips AN; EuroSIDA Study Group. (18 Feb 2005). Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS. 19:319-330.
  • Scriba TJ; Zhang HT; Brown HL; Oxenius A; Tamm N; Fidler S; Fox J; Weber JN; et alKlenerman P; Day CL; Lucas M; Phillips RE. (Feb 2005). HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest. 115:443-450. DOI.
  • Taylor GP; Bodéus M; Courtois F; Pauli G; Del Mistro A; Machuca A; Padua E; Andersson S; et alGoubau P; Chieco-Bianchi L; Soriano V; Coste J; Ades AE; Weber JN. (1 Jan 2005). The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr. 38:104-109.
  • Sukhanova AL; Kazennova EV; Rudinskiĭ NI; Mikhaĭlovich VM; Griadunov DA; Budilov AV; Bulavkina MA; Weber JN; et alPokrovskiĭ VV; Bobkov AF. (Nov 2004). [The genetic variability of the protease-encoding region in HIV-1 A isolates and in CRF03_AB recombinants as observed in the CIS territory]. Vopr Virusol. 49:4-9.
  • Roudinskii NI; Sukhanova AL; Kazennova EV; Weber JN; Pokrovsky VV; Mikhailovich VM; Bobkov AF. (Oct 2004). Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations. J Virol. 78:11276-11287. DOI.
  • Bobkov AF; Kazennova EV; Selimova LM; Khanina TA; Ryabov GS; Bobkova MR; Sukhanova AL; Kravchenko AV; et alLadnaya NN; Weber JN; Pokrovsky VV. (Oct 2004). Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A. J Med Virol. 74:191-196. DOI.
  • Ward H; Day S; Green A; Cooper K; Weber J. (Oct 2004). Declining prevalence of STI in the London sex industry, 1985 to 2002. Sex Transm Infect. 80:374-376. DOI.
  • Mackie N; Dustan S; McClure MO; Weber JN; Clarke JR. (Aug 2004). Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods. 119:73-78. DOI.
  • Mackie NE; Fidler S; Tamm N; Clarke JR; Back D; Weber JN; Taylor GP. (May 2004). Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. HIV Med. 5:180-184. DOI.
  • Balla-Jhagjhoorsingh SS; Koopman G; Mooij P; Koornstra W; McCormack S; Weber J; Pantaleo G; Heeney JL. (9 Apr 2004). Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA-CD62L-CCR7- memory T-helper cells. AIDS. 18:837-848.
  • White NC; Israel-Biet D; Coker RJ; Mitchell DM; Weber JN; Clarke JR. (Mar 2004). Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy. J Med Virol. 72:352-357. DOI.
  • Goon PK; Igakura T; Hanon E; Mosley AJ; Barfield A; Barnard AL; Kaftantzi L; Tanaka Y; et alTaylor GP; Weber JN; Bangham CR. (1 Feb 2004). Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol. 172:1735-1743.
  • Ward H; Weber J. (Oct 2003). Validity and utility of screening tests for STIs. Sex Transm Infect. 79:356-357.
  • Goon PK; Igakura T; Hanon E; Mosley AJ; Asquith B; Gould KG; Taylor GP; Weber JN; et alBangham CR. (Sep 2003). High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease. J Virol. 77:9716-9722.
  • Piñon JD; Klasse PJ; Jassal SR; Welson S; Weber J; Brighty DW; Sattentau QJ. (Sep 2003). Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol. 77:9922-9930.
  • Hodgson TA; Fidler SJ; Speight PM; Weber JN; Porter SR. (Aug 2003). Oral pemphigus vulgaris associated with HIV infection. J Am Acad Dermatol. 49:313-315.
  • Saito M; Braud VM; Goon P; Hanon E; Taylor GP; Saito A; Eiraku N; Tanaka Y; et alUsuku K; Weber JN; Osame M; Bangham CR. (15 Jul 2003). Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers. Blood. 102:577-584. DOI.
  • Beddows S; Galpin S; Kazmi SH; Ashraf A; Johargy A; Frater AJ; White N; Braganza R; et alClarke J; McClure M; Weber JN. (Jul 2003). Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol. 70:337-342. DOI.
  • Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; et alWeber JN; Phillips RE. (May 2003). Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity. J Virol. 77:6041-6049.
  • Cozzi-Lepri A; Phillips AN; Miller V; Katlama C; Ledergerber B; Vella S; Weber J; Bruun JN; et alKirk O; Clotet B; Lundgrens JD. (Apr 2003). Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 8:127-136.
  • Igakura T; Stinchcombe JC; Goon PK; Taylor GP; Weber JN; Griffiths GM; Tanaka Y; Osame M; et alBangham CR. (14 Mar 2003). Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 299:1713-1716. DOI.
  • Myint L; Ariyoshi K; Yan H; Frater AJ; Auwanit W; Pathipvanith P; Yamada K; Matsuda M; et alChiba T; Fujita K; McClure M; Weber JN; Sugiura W. (Dec 2002). Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother. 46:3861-3868.
  • Oxenius A; Price DA; Dawson SJ; Günthard HF; Fischer M; Perrin L; Ramirez E; Fagard C; et alHirschel B; Scullard G; Weber JN; McLean AR; Phillips RE; Swiss HIV cohort study. (22 Nov 2002). Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. AIDS. 16:2317-2322.
  • Fidler S; Oxenius A; Brady M; Clarke J; Cropley I; Babiker A; Zhang HT; Price D; et alPhillips R; Weber J. (18 Oct 2002). Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS. 16:2049-2054.
  • Riabov GS; Kazennova EV; Korepanova LB; Mal'tseva EA; Zhalnin VV; Krasnikova LA; Zverev SIA; Pokrovskiĭ VV; et alBobkov AF; Weber JN. (Jul 2002). [The HIV-infection outbreak in the town Lys'va (Perm region): homozygote genotype CCR5 delta32/CCR5 delta32 provides the high level of the persistence in the parenteral transmission of the virus]. Vopr Virusol. 47:13-16.
  • Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; et alLalonde R; Japour A; Brun S; Sun E; M98-863 Study Team. (27 Jun 2002). Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 346:2039-2046. DOI.
  • Frater AJ; Dunn DT; Beardall AJ; Ariyoshi K; Clarke JR; McClure MO; Weber JN. (24 May 2002). Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS. 16:1139-1146.
  • Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; et alCoutinho RA. (22 May 2002). Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine. 20:2343-2347.
  • Frater J; Dunn D; Weber JN; McClure MO. (1 May 2002). Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome. J Infect Dis. 185:1376. DOI.
  • Goon PK; Hanon E; Igakura T; Tanaka Y; Weber JN; Taylor GP; Bangham CR. (1 May 2002). High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood. 99:3335-3341.
  • Kaleebu P; French N; Mahe C; Yirrell D; Watera C; Lyagoba F; Nakiyingi J; Rutebemberwa A; et alMorgan D; Weber J; Gilks C; Whitworth J. (1 May 2002). Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis. 185:1244-1250. DOI.
  • Mocroft A; Phillips AN; Friis-Møller N; Colebunders R; Johnson AM; Hirschel B; Saint-Marc T; Staub T; et alClotet B; Lundgren JD; EuroSIDA study group. (Mar 2002). Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 7:21-30.
  • (Mar 2002). Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antivir Ther. 7:11-20.
  • Oxenius A; Fidler S; Brady M; Dawson SJ; Ruth K; Easterbrook PJ; Weber JN; Phillips RE; et alPrice DA. (Dec 2001). Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur J Immunol. 31:3782-3788. DOI.
  • Rowland-Jones SL; Pinheiro S; Kaul R; Hansasuta P; Gillespie G; Dong T; Plummer FA; Bwayo JB; et alFidler S; Weber J; McMichael A; Appay V. (1 Nov 2001). How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?. Immunol Lett. 79:15-20.
  • Smith D; Gow I; Colebunders R; Weller I; Tchamouroff S; Weber J; Boag F; Hales G; et alAdams S; Patou G; Cooper DA; 006 Study Group. (Oct 2001). Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med. 2:272-275.
  • Bobkov AF; Samokhvalov EI; Lvov DK; Bobkova MR; Povkrovsky VV; Weber JN. (22 Sep 2001). Absence of viral transmission in injecting drug users in Russia. Lancet. 358:1016-1017.
  • Fidler S; Frater J; Clarke J; Weber J. (15 Sep 2001). HIV-1 drug resistance in primary infections in the UK. BMJ. 323:632-633.
  • Frater AJ; Beardall A; Ariyoshi K; Churchill D; Galpin S; Clarke JR; Weber JN; McClure MO. (17 Aug 2001). Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS. 15:1493-1502.
  • Weber J; Nunn A; O'Connor T; Jeffries D; Kitchen V; McCormack S; Stott J; Almond N; et alStone A; Darbyshire J. (17 Aug 2001). 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS. 15:1563-1568.
  • Hanon E; Goon P; Taylor GP; Hasegawa H; Tanaka Y; Weber JN; Bangham CR. (1 Aug 2001). High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells. Blood. 98:721-726.
  • Oxenius A; Günthard HF; Hirschel B; Fidler S; Weber JN; Easterbrook PJ; Bell JI; Phillips RE; et alPrice DA. (Apr 2001). Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol. 31:1115-1121. DOI.
  • Frater AJ; Chaput CC; Beddows S; Weber JN; McClure MO. (Apr 2001). Simple detection of point mutations associated with HIV-1 drug resistance. J Virol Methods. 93:145-156.
  • Churchill DR; Slade PM; Youle M; Gazzard BG; Weber JN. (Mar 2001). A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection. J Antimicrob Chemother. 47:353-355.
  • Lacey CJN; Kitchen VS; Rosenstein I; Solanki S; Potter B; Weber JN. (1 Feb 2001). Are there critical endpoints in phase I/II trials of vaginal microbicides? A double-blind randomised controlled phase I study of 2% docusate sodium vaginal gel. AIDS. 15:S59-S60. Author weblink DOI.
  • Weber JN; Lacey CJ. (Feb 2001). The development of novel vaginal microbicides: from the bench to the clinic. AIDS. 15 Suppl 1:S35-S37.
  • Bobkov A; Kazennova E; Khanina T; Bobkova M; Selimova L; Kravchenko A; Pokrovsky V; Weber J. (10 Feb 2001). An HIV type 1 subtype A strain of low genetic diversity continues to spread among injecting drug users in Russia: study of the new local outbreaks in Moscow and Irkutsk. AIDS Res Hum Retroviruses. 17:257-261. DOI.
  • Bobkova MR; Kazennova EV; Selimova LM; Buravtsova EV; Lister S; Prilipov AG; Weber JN; Pokrovsky VV; et alBobkov AF. (Jan 2001). Serological approaches to subtyping of HIV-1 in injecting drug users in Russia: evidence of subtype homogeneity at the main sites of the epidemic. Int J STD AIDS. 12:34-40.
  • Hanon E; Goon P; Taylor GP; Hasegawa H; Tanaka Y; Weber JN; Bangham CRM. (1 Jan 2001). High production of interferon-gamma but not interleukin-2 by human T cell lymphotropic virus type I (HTLV-I)-infected peripheral blood mononuclear cells. AIDS RESEARCH AND HUMAN RETROVIRUSES. 17:S27-S27. Author weblink.
  • Saito M; Taylor GP; Saito A; Furukawa Y; Usuku K; Weber JN; Osame M; Bangham CR. (Jan 2001). In vivo selection of T-cell receptor junctional region sequences by HLA-A2 human T-cell lymphotropic virus type 1 Tax11-19 peptide complexes. J Virol. 75:1065-1071. DOI.
  • Saito M; Taylor GP; Saito A; Furukawa Y; Usuku K; Weber JN; Osame M; Bangham CRM. (1 Jan 2001). In vivo selection of TCR junctional region sequences by HLAA2/human T cell leukemia virus type-1 (HTLV-1) Tax11-19 peptide complexes. AIDS RESEARCH AND HUMAN RETROVIRUSES. 17:S61-S61. Author weblink.
  • Weber J. (2001). The pathogenesis of HIV-1 infection. Br Med Bull. 58:61-72.
  • Clarke JR; Galpin S; Braganza R; Ashraf A; Russell R; Churchill DR; Weber JN; McClure MO. (Dec 2000). Comparative quantification of diverse serotypes of HIV-1 in plasma from a diverse population of patients. J Med Virol. 62:445-449.
  • Ward H; Ison CA; Day SE; Martin I; Ghani AC; Garnett GP; Bell G; Kinghorn G; et alWeber JN. (25 Nov 2000). A prospective social and molecular investigation of gonococcal transmission. Lancet. 356:1812-1817. DOI.
  • Hanon E; Asquith RE; Taylor GP; Tanaka Y; Weber JN; Bangham CR. (1 Nov 2000). High frequency of viral protein expression in human T cell lymphotropic virus type 1-infected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 16:1711-1715. DOI.
  • Hanon E; Stinchcombe JC; Saito M; Asquith BE; Taylor GP; Tanaka Y; Weber JN; Griffiths GM; et alBangham CR. (Nov 2000). Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity. 13:657-664.
  • Bobkov AF; Kazennova EV; Selimova LM; Khanina TA; Bobkova MR; Ladnaia NN; Kravchenko AV; Pokrovskiĭ VV; et alWeber JN. (Nov 2000). [Nucleotide sequence of gag and env genes of human immunodeficiency virus type 1, found in Russia: detection of new recombinant variants]. Vopr Virusol. 45:17-20.
  • Stainsby CM; Lyall EGH; Taylor GP; Galpin S; Clarke JR; McClure MO; Weber JN. (1 Oct 2000). A significant number of uninfected infants can be HIV RNA (false) positive. AIDS. 14:S132-S132. Author weblink.
  • Galpin S; Beddows S; Johargy A; Ashraf A; Prater AJ; White N; Clarke J; McClure M; et alWeber JN. (1 Oct 2000). HIV-1 genetic subtypes and antiretroviral therapy resistance testing. AIDS. 14:S118-S118. Author weblink.
  • White N; Israel-Biet D; Coker R; Mitchell D; Weber JN; Clarke JR. (1 Oct 2000). Compartmentalisation of HIV-1 resistance mutations between the lung and blood. AIDS. 14:S118-S119. Author weblink.
  • Stainsby CM; Lyall EGH; Taylor GP; Galpin S; Clarke JR; McClure MO; Weber JN. (1 Oct 2000). A significant number of uninfected infants can be HIV RNA (false) pos-positive. AIDS. 14:S106-S106. Author weblink.
  • Clarke JR; Kaye S; Babiker AG; Hooker MH; Tedder R; Weber JN. (Aug 2000). Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. J Virol Methods. 88:117-124.
  • Frater AJ; Chaput CC; Weber JN; McClure MO. (7 Jul 2000). HIV-1 resistance genotyping by sequencing produces inconsistent results for mixed viral populations. AIDS. 14:1473-1475.
  • Ades AE; Parker S; Walker J; Weber JN. (1 Jul 2000). Serotype, parental country of birth, and ethnic status in unlinked anonymous neonatal HIV seroprevalence surveys. J Acquir Immune Defic Syndr. 24:292-294.
  • Ades AE; Parker S; Walker J; Edginton M; Taylor GP; Weber JN. (3 Jun 2000). Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study. BMJ. 320:1497-1501.
  • Kaleebu P; Yirrell D; French N; Lyagoba F; Rutebemberwa A; Cheingsong-Popov R; Gilks C; Biryahwaho B; et alWeber J; Whitworth J. (1 May 2000). An improved algorithm for determining HIV type 1 subtypes in a primary laboratory in Uganda. AIDS Res Hum Retroviruses. 16:621-625. DOI.
  • Furukawa Y; Bangham CR; Taylor GP; Weber JN; Osame M. (May 2000). Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Clin Exp Immunol. 120:307-316.
  • Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; et alWeber J; Profy A; Laga M; Kitchen V. (Apr 2000). A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect. 76:126-130.
  • Hanon E; Hall S; Taylor GP; Saito M; Davis R; Tanaka Y; Usuku K; Osame M; et alWeber JN; Bangham CRM. (1 Mar 2000). Abundant Tax protein expression in CD4+T cells infected with HTLV-I is prevented by cytotoxic T lymphocytes. LEUKEMIA. 14:547-547. Author weblink.
  • Hanon E; Hall S; Taylor GP; Saito M; Davis R; Tanaka Y; Usuku K; Osame M; et alWeber JN; Bangham CR. (15 Feb 2000). Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 95:1386-1392.
  • Bobkov AF; Lukashov VV; Goudsmit J; Weber JN. (10 Feb 2000). Silent mutation in the V3 region characteristic of HIV type 1 env subtype B strains from injecting drug users in the former Soviet Union. AIDS Res Hum Retroviruses. 16:291-294. DOI.
  • Fidler S; Weber J. (Feb 2000). T-cell activation: a cellular target for antiretroviral therapy. Eur J Clin Invest. 30:95-98.
  • Ainsworth JG; Hourshid S; Easterbrook PJ; Gilroy CB; Weber JN; Taylor-obinson D. (Feb 2000). Mycoplasma species in rapid and slow HIV progressors. Int J STD AIDS. 11:76-79.
  • McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; et alBeddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J. (18 Jan 2000). A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine. 18:1166-1177.
  • Gilson RJ; Shupack JL; Friedman-Kien AE; Conant MA; Weber JN; Nayagam AT; Swann RV; Pietig DC; et alSmith MH; Owens ML. (3 Dec 1999). A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS. 13:2397-2404.
  • Taylor GP; Hall SE; Navarrete S; Michie CA; Davis R; Witkover AD; Rossor M; Nowak MA; et alRudge P; Matutes E; Bangham CR; Weber JN. (Dec 1999). Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol. 73:10289-10295.
  • Babiker AG; Darbyshire JH; Gazzard BG; Hooker MH; Kitchen V; Newberry A; Peto TE; Tedder R; et alWeber J; Breckenridge A; Back D; Blatchford N; Gartland M; Jeffries D; Johnson M; Plummer K; Wills B; Loveday C; Weller IVD; Withnall R. (12 Nov 1999). A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial. AIDS. 13:2209-2217. Author weblink.
  • Clarke JR; Braganza R; Mirza A; Stainsby C; Ait-Khaled M; Wright A; Lyall H; Parker D; et alMcClure MO; Weber JN; Taylor GP. (Nov 1999). Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol. 59:364-368.
  • Ward H; Day S; Weber J. (Oct 1999). Risky business: health and safety in the sex industry over a 9 year period. Sex Transm Infect. 75:340-343.
  • Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; et alLarder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN. (1 Sep 1999). The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Res Hum Retroviruses. 15:1181-1189. DOI.
  • Taylor GP; Tosswill JH; Matutes E; Daenke S; Hall S; Bain BJ; Davis R; Thomas D; et alRossor M; Bangham CR; Weber JN. (1 Sep 1999). Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr. 22:92-100.
  • Louisirirotchanakul S; Beddows S; Cheingsong R; Shaffer N; Mastro TD; Likanonsakul S; Wasi C; Taylor GP; et alWeber JN. (1 Aug 1999). Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. J Acquir Immune Defic Syndr. 21:259-265.
  • Babiker A; Darbyshire JH; Gill ON; Johnson AM; Phillips AN; Porter K; Beral V; Brettle R; et alCarne C; Gilson RJC; Goldberg D; Hawkins DA; Jeffries D; Johnson MA; McMichael AJ; Mortimer PP; Pozniak A; Weber J; Wellsteed S. (9 Jul 1999). How soon after HIV seroconversion is antiretroviral therapy initiated?. AIDS. 13:1241-1247. Author weblink.
  • Kirchhoff F; Easterbrook PJ; Douglas N; Troop M; Greenough TC; Weber J; Carl S; Sullivan JL; et alDaniels RS. (Jul 1999). Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol. 73:5497-5508.
  • Abrams D; Allan D; Antunes F; Breckenridge A; Bruun J; Cameron W; Carbon C; Chalmers I; et alChang H; Chodakewitz J; Clendenin N; Clumeck N; Collier A; Collins G; Cooper E; Cooper D; Danner S; D'Aquila R; DeGruttola V; DeMasi R; Dee L; Deyton L; Dixon D; Farthing C; Feinberg J; Fischl M; Flepp M; Gartland M; Gatell J; Gazzard B; Goebel F; Gotzsche P; Gringeri A; Hall D; Hamilton J; Hammer S; Hartigan P; Heath-Chiozzi M; Henry K; Hill A; Hirschel B; Ioannidis J; Kahn J; Katlama C; Katzenstein D; Killen J; King E; de Loes SK; Kravcik S; Lange J; Leavitt R; Leonard J; Maeland A; Mannucci P; Mathiesen L; McDade H; Meibohn A; Melander H; Merigan T; Mulder J; Myers M; Neaton J; Nessling M; Perrin L; Pettinelli C; Phair J; Phillips A; Pinching A; Poppa A; Power L; Reiss P; Richman D; Rooney J; Rousseau F; Rutherford G; Salgo M; Sandstrom E; Saravolatz L; Savidge G; Schnittman S; Schooley R; Seligmann M; Simberkoff M; Skowron G; Slade P; Smith D; Smith RP; Soriano V; Stanley K; Stingl G; Stoffels P; Struthers L; Tierney C; Thompson M; Van der Broeck R; Van Leeuven R; Van Weverling G; Veenstra J; Vella S; Volberding P; Weber J; Winslow D; Yeni P; Yeo J; Dormont J; Sande M; Weller I; Babiker A; Collins R; Darbyshire J; Duncan W; Foulkes M; Hughes M; Peto R; Peto T; Walker S. (12 Jun 1999). Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. LANCET. 353:2014-2025. Author weblink.
  • Heeney JL; Beverley P; McMichael A; Shearer G; Strominger J; Wahren B; Weber J; Gotch F. (Jun 1999). Immune correlates of protection from HIV and AIDS - more answers but yet more questions. Immunol Today. 20:247-251.
  • Churchill D; Weber J. (May 1999). Measurement of plasma HIV viral load--clinical applications. J Infect. 38:147-150.
  • Adams GB; Pym AS; Poznansky MC; McClure MO; Weber JN. (10 Apr 1999). The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. AIDS Res Hum Retroviruses. 15:551-559. DOI.
  • Aboulker JP; Babiker AG; Flandre P; Gazzard B; Loveday C; Nunn AJ; Goudsmit J; Huraux JM; et alvan der Noorda J; Weiss R; Boucher C; Schurrman R; Brun-Vezinet F; Descamps D; Jeffries D; Tedder R; Weber J; Darbyshire JH; Reiss P; Weverling G. (1 Apr 1999). An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS. 13:565-573.
  • Jeffery KJ; Usuku K; Hall SE; Matsumoto W; Taylor GP; Procter J; Bunce M; Ogg GS; et alWelsh KI; Weber JN; Lloyd AL; Nowak MA; Nagai M; Kodama D; Izumo S; Osame M; Bangham CR. (30 Mar 1999). HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 96:3848-3853.
  • Jones GJ; von Hoegen P; Weber J; Rees AD. (Mar 1999). Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D. J Infect Dis. 179:558-566. DOI.
  • Churchill D; Weber J. (Mar 1999). Antiretroviral drug guidelines for the treatment of HIV infection: should protease inhibitors always be included in the initial regimen or not?. BioDrugs. 11:147-153.
  • Beddows S; Lister S; Cheingsong R; Bruck C; Weber J. (Feb 1999). Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol. 73:1740-1745.
  • Aboulker JP; Babiker AG; Brun-Vezinet F; Darbyshire JH; Flandre P; Gazzard B; Nunn AJ; Goodall R; et alAber V; Bragman K; Breckenridge AM; Carbon C; Charreau I; Chene G; Collis P; Cooper D; Dormont J; Fiddian P; Flepp M; Goebel FD; Hooker M; Lange J; Luthy R; Peto TEA; Reiss P; Seligmann M; Stone AB; Thomis J; Vella S; Walckenaer G; Warrell D; Weller IVD; Wilber R; Yeni P; Yeo J; Withnall R; Goudsmit J; Huraux JM; van der Noorda J; Weiss R; Boucher C; Schuurman R; Descamps D; Jeffries D; Tedder R; Weber J; Krzyanowski C; Weverling G. (14 Jan 1999). HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS. 13:57-65. Author weblink.
  • Day S; Ward H; Ison C; Bell G; Weber J. (Dec 1998). Sexual networks: the integration of social and genetic data. Soc Sci Med. 47:1981-1992.
  • Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; et alWeber J. (1 Dec 1998). Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol. 19:315-320.
  • Bobkov A; Kazennova E; Selimova L; Ladnaya N; Kravchenko A; Foley B; Morrison I; Pokrovsky V; et alWeber J; Cheingsong-Popov R. (20 Nov 1998). HIV type 1 gag D/env G recombinants in Russia. AIDS Res Hum Retroviruses. 14:1597-1599.
  • Tosswill JH; Taylor GP; Clewley JP; Weber JN. (Nov 1998). Quantification of proviral DNA load in human T-cell leukaemia virus type I infections. J Virol Methods. 75:21-26.
  • Day S; Ward H; Ghani A; Bell G; Goan U; Parker M; Claydon E; Ison C; et alKinghorn G; Weber J. (Nov 1998). Sexual histories, partnerships and networks associated with the transmission of gonorrhoea. Int J STD AIDS. 9:666-671.
  • McBride MO; Fischer PB; Sumiya M; McClure MO; Turner MW; Skinner CJ; Weber JN; Summerfield JA. (Nov 1998). Mannose-binding protein in HIV-seropositive patients does not contribute to disease progression or bacterial infections. Int J STD AIDS. 9:683-688.
  • Weber J. (1 Nov 1998). Vaginal virucides for the prevention of HIV transmission. AIDS. 12:S5-S5. Author weblink.
  • Clarke JR; Braganza R; Mirza A; Ait-Khaled M; Wright A; Weber JN; McClure MO; Taylor GP. (1 Nov 1998). High frequency of resistance mutations in pregnant women on dual antiretroviral therapy. AIDS. 12:S20-S20. Author weblink.
  • Churchill DR; Pym AS; Babiker AG; Back DJ; Weber JN. (Nov 1998). Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol. 46:518-519.
  • Bobkov A; Kazennova E; Selimova L; Bobkova M; Khanina T; Ladnaya N; Kravchenko A; Pokrovsky V; et alCheingsong-Popov R; Weber J. (20 May 1998). A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: identification of subtype A, subtype B, and novel gagA/envB recombinants. AIDS Res Hum Retroviruses. 14:669-676.
  • Rosenstein IJ; Stafford MK; Kitchen VS; Ward H; Weber JN; Taylor-Robinson D. (May 1998). Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis. 177:1386-1390.
  • Beral V; Babiker A; Brettle R; Carne C; Darbyshire JH; Evans BG; Gill ON; Gilson RJC; et alGoldberg D; Hawkins DA; Jeffries D; Johnson AM; Johnson MA; McMichael AJ; Mortimer PP; Phillips AN; Porter K; Pozniak A; Weber J; Wellsteed S. (16 Apr 1998). The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS. 12:659-667. Author weblink.
  • Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS. (1 Apr 1998). Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 17:327-331.
  • Tedder RS; Kaye S; Loveday C; Weller IV; Jeffries D; Norman J; Weber J; Bourelly M; et alFoxall R; Babiker A; Darbyshire JH. (Apr 1998). Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol. 36:1056-1063.
  • Ait-Khaled M; Lyall EG; Stainsby C; Taylor GP; Wright A; Weber JN; McClure MO; Tudor-Williams G. (Apr 1998). Intrapartum mucosal exposure to human immunodeficiency virus type 1 (HIV-1) of infants born to HIV-1-infected mothers correlates with maternal plasma virus burden. J Infect Dis. 177:1097-1100.
  • Cheingsong-Popov R; Osmanov S; Pau CP; Schochetman G; Barin F; Holmes H; Francis G; Ruppach H; et alDietrich U; Lister S; Weber J. (1 Mar 1998). Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. AIDS Res Hum Retroviruses. 14:311-318.
  • Lyall EG; Stainsby C; Taylor GP; Ait-Khaled M; Bingham S; Evans JA; Wright A; Weber JN; et alMcClure MO; Walters S; Tudor-Williams G. (24 Jan 1998). Review of uptake of interventions to reduce mother to child transmission of HIV by women aware of their HIV status. BMJ. 316:268-270.
  • Hoelscher M; Hanker S; Barin F; Cheingsong-Popov R; Dietrich U; Jordan-Harder B; Olaleye D; Nägele E; et alMarkuzzi A; Mwakagile D; Minja F; Weber J; Gürtler L; Von Sonnenburg F. (20 Jan 1998). HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping. AIDS Res Hum Retroviruses. 14:139-149.
  • Kazennova EV; Aarons E; Selimova LM; Ladnaia NN; Kravchenko AV; Zhemchugov VE; Chaingon-Popov R; Weber J; et alPokrovskiĭ VV; Bobkov AF. (Jan 1998). [Comparative analysis of distribution of mutant alleles of the gene coding for the CCR-5 chemokine receptor, among people in Russia, infected and not infected with HIV-1]. Vopr Virusol. 43:30-32.
  • Weber J. (1998). HIV and sexually transmitted disease. Br Med Bull. 54:717-729.
  • Cheingsong-Popov R; Williamson C; Lister S; Morris L; van Harmelen J; Bredell H; Wood R; Sonnenberg P; et alvan der Ryst E; Martin D; Weber J. (28 May 1998). Usefulness of HIV-1 V3 serotyping in studying the HIV-1 epidemic in South Africa. AIDS. 12:949-950.
  • Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J. (Jan 1998). Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 79 ( Pt 1):77-82.
  • Asjo B; Barin F; Biberfeld G; Bradac J; Buve A; Dielly S; Fontanet A; Gurtler L; et alvanderGroen G; Hoelscher M; HolmHansen C; Hu D; JordanHarder B; Kaleebu P; Kaptue L; Korber B; Levin A; Lukashov V; Lyamuya E; Mboup S; McCutchan FE; Jackson HM; Mhalu F; Mkwera H; Msobi N; Mullins J; Mwakagile D; Nandi J; Nkengasong J; Nukulila T; Osmanov S; Peeters M; Pletschette M; Scarlatti G; Shao J; Shao YM; Sonnenburg FV; Sutherland D; Tennagashaw M; Urassa W; deVincenzi I; Weber J; Williamson C; Wolf H. (1 Dec 1997). HIV-1 subtypes: implications for epidemiology, pathogenicity, vaccines and diagnostics - Workshop report from the European Commission (DG XII, INCO-DC) and the Joint United Nations Programme on HIV/AIDS. AIDS. 11:17-36. Author weblink.
  • Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN. (Nov 1997). A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect. 35:231-235.
  • Pope M; Ho DD; Moore JP; Weber J; Dittmar MT; Weiss RA. (31 Oct 1997). Different subtypes of HIV-1 and cutaneous dendritic cells. Science. 278:786-788.
  • Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; et alKrzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ. (4 Oct 1997). HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet. 350:983-990.
  • Weber J. (Oct 1997). Trials and tribulations: ethical dilemmas in HIV therapy. Curr Opin Immunol. 9:625-627.
  • Dittmar MT; Simmons G; Hibbitts S; O'Hare M; Louisirirotchanakul S; Beddows S; Weber J; Clapham PR; et alWeiss RA. (Oct 1997). Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J Virol. 71:8008-8013.
  • Bobkov A; Cheingsong-Popov R; Selimova L; Ladnaya N; Kazennova E; Kravchenko A; Fedotov E; Saukhat S; et alZverev S; Pokrovsky V; Weber J. (20 Sep 1997). An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses. 13:1195-1201.
  • Weber J. (26 Jul 1997). Distinguishing between response to HIV vaccine and response to HIV. Lancet. 350:230-231. DOI.
  • Louisirirotchanakul S; Bobkov A; Shaffer N; Mastro TD; Wasi C; Weber J; Cheingsong-Popov R. (10 Jun 1997). Sequence analysis of an HIV type 1 env subtype E isolate from Thailand with discordant V3-loop serotyping. AIDS Res Hum Retroviruses. 13:807-809.
  • Ives KJ; Jacobsen H; Galpin SA; Garaev MM; Dorrell L; Mous J; Bragman K; Weber JN. (Jun 1997). Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother. 39:771-779.
  • Bobkov A; Cheingsong-Popov R; Selimova L; Ladnaya N; Kazennova E; Kravchenko A; Pokrovsky V; Weber J. (20 May 1997). HIV type 1 subtype E in Russia. AIDS Res Hum Retroviruses. 13:725-727.
  • Gazzard BG; Moyle GJ; Weber J; Johnson M; Bingham JS; Brettle R; Churchill D; Fisher M; et alGriffin G; Jefferies D; King E; Gormer R; Lee C; Pozniak A; Smith JR; TudorWilliams G; Williams I. (12 Apr 1997). British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. LANCET. 349:1086-1092. Author weblink DOI.
  • Bobkov AF; Pokrovskiĭ VV; Selimova LM; Kazennova EV; Karaseva NG; Ladnaia NN; Kravchenko AV; Cheingsong-Popov R; et alWeber J. (Apr 1997). [Genetic diversity of human immunodeficiency virus type 1 (HIV-1) in Russia]. Dokl Akad Nauk. 353:822-824.
  • Aarons E; Fernandez M; Rees A; McClure M; Weber J. (Apr 1997). CC-chemokine receptor 5 genotypes and in vitro susceptibility to HIV-1 of a cohort of British HIV-exposed uninfected homosexual men. AIDS. 11:688-689.
  • Anderson R; BarreSinoussi F; Bradac J; Burke DS; Essex M; Fenyo EM; GalvaoCastro B; Hu DJ; et alJaffe H; Karamov E; Kuiken C; Kunanusont C; Laga M; Lower J; Mastro T; McCutchan FE; Opio A; Pauli G; Sutherland D; Schwartlander B; deVincenzi I; vonBriesen H; Wasi C; Weber J; Piot P; Carael M; Osmanov S. (15 Mar 1997). Implications of HIV variability for transmission: Scientific and policy issues. AIDS. 11:A1-A15. Author weblink.
  • Stafford MK; Cain D; Rosenstein I; Fontaine EA; McClure M; Flanagan AM; Smith JR; Taylor-Robinson D; et alWeber J; Kitchen VS. (1 Mar 1997). A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide. J Acquir Immune Defic Syndr Hum Retrovirol. 14:213-218.
  • Fernandez MH; Fidler SJ; Pitman RJ; Weber JN; Rees AD. (Mar 1997). CD4+ T-cell recognition of diverse clade B HIV-1 isolates. AIDS. 11:281-288.
  • Bobkov AF; Pokrovsky VV; Selimova LM; Kazennova YV; Karaseva NG; Ladnaya NN; Kravchenko AV; CheingsongPopov R; et alWeber J. (1 Jan 1997). Subtyping and phylogenetic analysis of HIV-1 isolates from Russia. VOPROSY VIRUSOLOGII. 42:13-16. Author weblink.
  • Churchill DR; Galpin SA; Harvey J; Weber JN. (1 Nov 1996). Short-term changes in plasma HIV RNA following chemotherapy for lymphoma. AIDS. 10:P128-P128. Author weblink.
  • Ali M; Taylor GP; Pitman RJ; Parker D; Rethwilm A; Cheingsong-Popov R; Weber JN; Bieniasz PD; et alBradley J; McClure MO. (10 Oct 1996). No evidence of antibody to human foamy virus in widespread human populations. AIDS Res Hum Retroviruses. 12:1473-1483.
  • Paige DG; Price DA; Crook T; Main J; Fry L; Weber JN. (May 1996). Isolated cutaneous non-tuberculous mycobacterial infection as a manifestation of AIDS. Clin Exp Dermatol. 21:226-229.
  • McClure MO; Goulder PJ; Ogg G; McMichael AJ; Weber JN. (20 Apr 1996). HIV clearance in infants. Lancet. 347:1122.
  • Churchill DR; Mann D; Coker RJ; Miller RF; Glazer G; Goldin RD; Lucas SB; Weber JN; et alDe Cock KM. (Feb 1996). Fatal haemorrhage following liver biopsy in patients with HIV infection. Genitourin Med. 72:62-64.
  • Kitchen VS; Skinner C; Ariyoshi K; Lane EA; Duncan IB; Burckhardt J; Burger HU; Bragman K; et alPinching AJ; Weber JN. (15 Apr 1995). Safety and activity of saquinavir in HIV infection. Lancet. 345:952-955.
  • Ariyoshi K; Bloor S; Bieniasz PD; Bourrelly M; Foxall R; Weber JN. (May 1994). Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). J Med Virol. 43:28-32.
  • Horner PJ; McBride M; Coker RJ; Crowley S; Harris JR; Murphy SM; Weber JN; Renton AM. (Oct 1993). Outpatient follow-up in women with HIV infection in Parkside Health Authority (UK). Genitourin Med. 69:370-372.
  • Cheingsong-Popov R; Bobkov A; Garaev MM; Kaleebu P; Callow D; Rzhiminova A; Saukhat SR; Burdajev NP; et alKolomijets ND; Weber JN. (Aug 1993). Identification of human immunodeficiency virus type 1 subtypes and their distribution in the Commonwealth of Independent States (Former Soviet Union) by serologic V3 peptide-binding assays and V3 sequence analysis. J Infect Dis. 168:292-297.
  • Bieniasz PD; Ariyoshi K; Bourelly MA; Bloor S; Foxall RB; Harwood EC; Weber JN. (Jun 1993). Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individuals. AIDS. 7:803-806.
  • Katseni VL; Gilroy CB; Ryait BK; Ariyoshi K; Bieniasz PD; Weber JN; Taylor-Robinson D. (30 Jan 1993). Mycoplasma fermentans in individuals seropositive and seronegative for HIV-1. Lancet. 341:271-273.
  • Lau RK; Hill A; Jenkins P; Caun K; Forster SM; Weber JN; McManus TJ; Harris JR; et alJeffries DJ; Pinching AJ. (Jul 1992). Eight year prospective study of HIV infection in a cohort of homosexual men--clinical progression, immunological and virological markers. Int J STD AIDS. 3:261-266.
  • Lau RK; Jenkins P; Caun K; Forster SM; Weber JN; McManus TJ; Harris JR; Jeffries DJ; et alPinching AJ. (Jul 1992). Trends in sexual behaviour in a cohort of homosexual men: a 7 year prospective study. Int J STD AIDS. 3:267-272.
  • Coker RJ; Hellyer TJ; Brown IN; Weber JN. (May 1992). Clinical aspects of mycobacterial infections in HIV infection. Res Microbiol. 143:377-381.
  • Shaunak S; Weber JN. (Apr 1992). The retroviruses: classification and molecular biology. Baillieres Clin Neurol. 1:1-21.
  • MCCLURE MO; MOORE JP; BLANC DF; SCOTTING P; COOK GMW; KEYNES RJ; WEBER JN; DAVIES D; et alWEISS RA. (1 Jan 1992). INVESTIGATIONS INTO THE MECHANISM BY WHICH SULFATED POLYSACCHARIDES INHIBIT HIV-INFECTION INVITRO. AIDS RESEARCH AND HUMAN RETROVIRUSES. 8:19-26. Author weblink DOI.
  • Bowness P; Davies KA; Tosswill J; Bunn CC; MacAlpine L; Weber JN; Walport MJ. (Apr 1991). Autoimmune disease and HTLV-1 infection. Br J Rheumatol. 30:141-143.
  • PINCHING AJ; JEFFRIES DJ; HARRIS JRW; SWIRSKY D; WEBER JN. (27 Sep 1990). HIV AND AIDS. NATURE. 347:324-324. Author weblink DOI.
  • Weber JN; Weiss RA. (Oct 1988). HIV infection: the cellular picture. Sci Am. 259:100-109.
  • WEBER JN; WEISS RA. (1 Oct 1988). HIV INFECTION - THE CELLULAR PICTURE. SCIENTIFIC AMERICAN. 259:100-&. Author weblink.
  • Forster SM; Osborne LM; Cheingsong-Popov R; Kenny C; Burnell R; Jeffries DJ; Pinching AJ; Harris JR; et alWeber JN. (Dec 1987). Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection. AIDS. 1:235-240.

Books

  • Weber JN; Fenyo EM. WHO-UNAIDS Guidelines for Standard HIV Isolation and Characterisation Procedures. (2002).

Conferences

  • McKay PF; Cope A; Swales J; Joseph S; Esteban M; Tatoud R; Carter D; Weber J; et alShattock RJ. HIV CN54gp140 +GLA Significantly Enhances Vaccine Antigen-Specific T and B Cell Immune Responses After Priming with DNA and MVA. AIDS Vaccine 2011, 12 Sep 2011 - 15 Sep 2011. 27. Mary Ann Liebert, Inc. (2011). DOI.
  • Wallis CL; Viana R; St John EP; Simen BB; Ramjee G; Fidler S; Rees H; Weber J; et alStevens W. Presence of low abundance drug-resistant mutations in recently infected HIV-1 subtype C patients from South Africa. Workshop on International HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 8 Jul 2010 - 12 Jul 2010. 15:A35-A35. INT MEDICAL PRESS LTD (1 Jan 2010). Author weblink.
  • Levy Y; Ellefsen K; Stoeehr W; Bart P; Lelievre J; Launay O; Wolf H; Weber J; et alChene G; Pantaleo G. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the EV03/ANRS Vac20 Phase I/II Trial. AIDS Vaccine 2010, 28 Sep 2010 - 1 Oct 2010. 26:A10-A10. MARY ANN LIEBERT INC (1 Oct 2010).
  • Weber J; Rose JD; Wylie D; Vazquez AC; Rhea AM; Winner D; Margot N; McColl D; et alMiller M; Quinones-Mateu ME. Resistance mutations in protease, reverse transcriptase and integrase genes: do they have an epistatic effect on drug susceptibility and/or HIV-1 replicative fitness?. International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop, 8 Jun 2010 - 12 Jun 2010. 15:A94-A94. INT MEDICAL PRESS LTD (1 Jan 2010).
  • Vazquez AC; Weber J; Baba M; Winner D; Rose JD; Rhea AM; Wyhe D; Urata Y; et alQuinones-Mateu ME. Antiviral activity profile and characterization of mutations associated with resistance to a novel NRTI (OBP-601, Festinavir (R)) and their effect on HIV-1 replicative fitness. International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop, 8 Jun 2010 - 12 Jun 2010. 15:A66-A66. INT MEDICAL PRESS LTD (1 Jan 2010).
  • Weber J; Rose JD; Vazquez AC; Winner D; Rhea AM; Wylie D; Salzwedel K; Quinones-Mateu ME. Characterization of mutations associated with resistance to MPC-4326 and their effecy on HIV-1 replicative fitness. International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop, 8 Jun 2010 - 12 Jun 2010. 15:A56-A56. INT MEDICAL PRESS LTD (1 Jan 2010).
  • Wallis CL; Viana R; St John EP; Simen BB; Ramjee G; Fidler S; Rees H; Weber J; et alStevens W. Presence of low abundance drug-resistant mutations in recently infected HIV-1 subtype C patients from South Africa. International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop, 8 Jun 2010 - 12 Jun 2010. 15:A35-A35. INT MEDICAL PRESS LTD (1 Jan 2010).
  • Thomson EC; Main J; Weber JN; Fleming VM; Klenerman P; Karayannis P. PREDICTING CLEARANCE OF ACUTE HCV IN HIV-POSITIVE PATIENTS. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, 30 Oct 2009 - 3 Nov 2009. 50:343A-343A. JOHN WILEY & SONS INC (1 Oct 2009). Author weblink.
  • Schmidt C; Kochhar S; Excler J; Smith C; McMichael A; Hanke T; Bwayo J; Jaoko W; et alWeber J; Kaleebu P; Peters B; Pantaleo G; Vardas E; Vasan S; Keefer M; Ramanathan V; Boyle R; Fast P. Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA). AIDS Vaccine 2008 Conference, 13 Oct 2008 - 16 Oct 2008. 24:106-107. MARY ANN LIEBERT INC (1 Oct 2008). Author weblink.
  • Wagner R; Wild J; Bieler K; Wolf H; Mooij P; Heeney J; Weber J; Harrari A; et alPantaleo G. Development and immunogenicity of RNA- and codon-optimized HIV candidate Vaccines in phase I clinical trials. 15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, 27 Oct 2007 - 30 Oct 2007. 18:961-961. MARY ANN LIEBERT INC (1 Oct 2007). Author weblink.
  • Ulsenheimer A; Lucas M; Pfaffero K; Heeg MH; Gaudieri S; Gruener N; Rauch A; Gerlach T; et alJung MC; Zachoval R; Pape GR; Santantonio T; Nitschko H; Baumertlo TF; Thimme R; Weber JN; Klenerman P; Diepolder HM. Exhaustion of virus specific CD4+T cells during acute hepatitis C. 42th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, 11 Apr 2007 - 15 Apr 2007. 46:S295-S295. ELSEVIER SCIENCE BV (1 Jan 2007). Author weblink DOI.
  • Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Shafer RW; Van Laethem K; Carvalho AP; et alWynhoven B; Cane P; Clarke J; Snoeck J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Brun-Vezinet F; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Schapiro JM; Katzenstein D; Kantor R; Vandamme AM. Interactions between nevirapine resistance mutations and NRTI resistance mutations. 14th International HIV Drug Resistance Workshop. 10:S144-S144. (Jan 2005).
  • Kantor R; DeLong A; Shafer RW; Carvalho AP; Wynhoven B; Cane P; Sirivichayakul S; Soares MA; et alSnoeck J; Rudich H; Rodrigues R; Holguin A; Ariyoshi K; Bouzas MB; Cahn P; Sugiura W; Soriano V; Brigido LF; Grossman Z; Morris L; Vandamme AM; Tanuri A; Phanuphak P; Weber J; Pillay D; Harrigan PR; Camacho R; Schapiro JM; Hogan J; Katzenstein DA. Selection of resistance following first-line antiretroviral regimens among HIV-1 subtypes. 14th International HIV Drug Resistance Workshop. 10:S146-S146. (2005).
  • Kantor R; DeLong A; Shafer RW; Carvalho AP; Wynhoven B; Cane P; Sirivichayakul S; Soares MA; et alSnoeck J; Rudich H; Rodrigues R; Holguin A; Ariyoshi K; Bouzas MB; Cahn P; Sugiura W; Soriano V; Brigido LF; Grossman Z; Morris L; Vandamme AM; Tanuri A; Phanuphak P; Weber J; Pillay D; Harrigan PR; Camacho R; Schapiro J; Hogan J; Katzenstein DA. Selection of resistance following first-line anti-retroviral regimens among HIV-1 subtypes. 14th International HIV Drug Resistance Workshop. 10:S146-S146. (Jan 2005).
  • Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Shafer RW; Van Laethem K; Carvalho AP; et alWynhoven B; Cane P; Clarke J; Snoeck J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Brun-Vezinet F; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Schapiro JM; Katzenstein D; Kantor R; Vandamme AM. Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G. 14th International HIV Drug Resistance Workshop. 10:S132-S132. (2005).
  • Deforche K; Camacho R; Grossman Z; Silander T; Soares MA; Shafer RW; Van Laethem K; Carvalho AP; et alWynhoven B; Cane P; Clarke J; Snoeck J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Brun-Vezinet F; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Schapiro JM; Katzenstein D; Kantor R; Vandamme AM. Interactions between nevirapine resistance mutations and NRTI resistance mutations. 14th International HIV Drug Resistance Workshop. 10:S144-S144. (2005).
  • Deforche K; Camacho R; Grossman Z; Silander T; Soares M; Shafer RW; Van Laethem K; Carvalho AP; et alWynhoven B; Cane P; Clarke J; Snoeck J; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas M; Brun-Vezinet F; Cahn P; Brigido LF; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Schapiro JM; Katzenstein D; Kantor R; Vandamme AM. Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G. 14th International HIV Drug Resistance Workshop. 10:S132-S132. (Jan 2005).
  • Snoeck J; Kantor R; Shafer RW; Van Laethem K; Deforche K; Carvalho AP; Wynhoven B; Soares MA; et alCane P; Clarke J; Pillay C; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Brun-Vezinet F; Reid C; Cahn P; Brigido LF; Grossman Z; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Camacho R; Schapiro JM; Katzenstein D; Vandamme AM. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent. 13th International HIV Drug Resistance Workshop, 8 Jun 2004 - 12 Jun 2004. 9:U91-U92. INT MEDICAL PRESS LTD (1 Aug 2004). Author weblink.
  • Snoeck J; Kantor R; Shafer RW; Derdelinckx I; Carvalho AP; Wynhoven B; Soares MA; Cane P; et alClarke J; Pillay C; Sirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Van Laethem K; Brun-Vezinet F; Reid C; Cahn P; Brigido LF; Grossman Z; Soriano V; Sugiura W; Phanuphak P; Morris L; Weber J; Pillay D; Tanuri A; Harrigan PR; Camacho R; Schapiro JM; Katzenstein D; Vandamme AM. Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes. 12th International HIV Drug Resistance Workshop. 8:U98-U99. (Jun 2003).
  • Kantor R; Carvalho AP; Wynhoven B; Soares MA; Cane P; Clarke J; Snoeck J; Pillay C; et alSirivichayakul S; Ariyoshi K; Holguin A; Rudich H; Rodrigues R; Bouzas MB; Cahn P; Brigido LF; Grossman Z; Soriano V; Sugiura W; Phanuphak P; Morris L; Vandamme AM; Weber J; Pillay D; Tanuri A; Harrigan PR; Camacho R; Schapiro JM; Shafer RW; Katzenstein D. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. 12th International HIV Drug Resistance Workshop. 8:U58-U59. (Jun 2003).
  • Taylor GP; Goon P; Usuku K; Barfield A; Green H; Babiker A; Bangham CR; Weber JN. The bridge study - A double-blind placebo controlled trial of zidovudine plus lamivudine for treatment of patients with HTLV-I-associated myelopathy. 11th International Conference on Human Retrovirology: HTLV and Related Viruses, 9 Jun 2003 - 12 Jun 2003. 19:S13-S14. MARY ANN LIEBERT INC PUBL (1 Jan 2003). Author weblink.
  • Igakura T; Stinchcombe JC; Goon PK; Taylor GP; Weber JN; Griffiths GM; Tanaka Y; Osame M; et alBangham CR. HTLV-I spreads between lymphocytes by virus-induced polarization of the cytoskeleton. 11th International Conference on Human Retrovirology: HTLV and Related Viruses. 19:S15-S15. (2003).
  • Weber J. Characterisation of broadly neutralising polyclonal antisera from HIV-1+ subjects. 10th Anniversary of the Cent Gardes Meeting - Retroviruses of Human AIDS and Related Animal Diseases. 81-85. (1996).
  • WEBER J; CHEINGSONGPOPOV R; PANAGIOTIDI C. HIV CORE PROTEINS AND PATHOGENESIS. SYMP ON HUMAN RETROVIRUSES, 4 Feb 1989 - 11 Feb 1989. 119:207-216. WILEY-LISS, INC (1 Jan 1990). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook